CheckMate 078: Patient-Reported Outcomes (PROs) With Nivolumab vs Docetaxel in Advanced Non-Small Cell Lung Cancer (NSCLC)

被引：0
|
作者：
Wu, Y. [1 ,2 ]
Chang, J. [3 ]
Zhang, L. [4 ]
Tu, H. [1 ,2 ]
Wu, L. [5 ]
Feng, J. [6 ]
Lu, S. [7 ]
Zhou, C. [8 ]
Wang, J. [9 ,10 ]
Mok, T. [11 ]
Taylor, F. [12 ]
Mossman, B. [12 ]
Penrod, J. [13 ]
Lawrance, R. [14 ]
Blum, S. [13 ]
Wang, P. F. [13 ]
Cheng, Y. [15 ]
机构：
[1] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
[2] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China
[3] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[4] Sun Yat Sen Univ, Guangzhou, Guangdong, Peoples R China
[5] Hunan Canc Hosp, Changsha, Hunan, Peoples R China
[6] Jiangsu Canc Hosp, Nanjing, Jiangsu, Peoples R China
[7] Shanghai Jiao Tong Univ Shanghai, Shanghai Chest Hosp, Shanghai Lung Canc Ctr, Shanghai, Peoples R China
[8] Shanghai Pulm Hosp, Shang, Peoples R China
[9] Chinese Acad Med Sci, Natl Canc Ctr, Natl Clin Res Ctr Canc, Canc Hosp, Beijing, Peoples R China
[10] Peking Union Med Coll, Beijing, Peoples R China
[11] Chinese Univ Hong Kong, Shatin, Hong Kong, Peoples R China
[12] Adelphi Values, Boston, MA USA
[13] Bristol Myers Squibb, Princeton, NJ USA
[14] Adelphi Values, Bollington, England
[15] Jilin Canc Hosp, Changchun, Jilin, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 12期
关键词：
Advanced NSCLC; Nivolumab; Docetaxel; Patient-Reported Outcomes;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OA10
引用
收藏
页码：S1047 / S1048
页数：2
相关论文
共 50 条
  • [1] Phase 3, randomized trial (CheckMate 057) of nivolumab vs docetaxel in advanced non-squamous (non-SQ) non-small cell lung cancer (NSCLC): subgroup analyses and patient reported outcomes (PROs)
    Horn, L.
    Brahmer, J.
    Reck, M.
    Borghaei, H.
    Spigel, D. R.
    Steins, M.
    Ready, E.
    Chow, L. Q.
    Vokes, E. E.
    Felip, E.
    Holgado, E.
    Barlesi, F.
    Kohlhaeufl, M.
    Burgio, M. A.
    Fayette, J.
    Gettinger, S. N.
    Harbison, C. T.
    Li, A.
    Finckenstein, F. G.
    Paz-Ares, L.
    ANNALS OF ONCOLOGY, 2015, 26 : 125 - 125
  • [2] Three-year follow-up and patient-reported outcomes from CheckMate 078: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer
    Chang, Jianhua
    Wu, Yi-Long
    Lu, Shun
    Wang, Jie
    Mok, Tony
    Zhang, Li
    Feng, Jifeng
    Wu, Lin
    Tu, Hai-Yan
    Zhang, Yiping
    Luft, Alexander
    Zhou, Jian-ying
    Ma, Zhiyong
    Lu, You
    Hu, Chengping
    Shi, Yuankai
    Poddubskaya, Elena
    Soo, Ross A.
    Chia, Yee Hong
    Penrod, John R.
    Taylor, Fiona
    Lawrance, Rachael
    Blum, Steven, I
    Sun, Xiaowu
    Juarez-Garcia, Ariadna
    Moreno-Koehler, Alejandro
    Li, Ang
    Li, Amy
    Cheng, Ying
    LUNG CANCER, 2022, 165 : 71 - 81
  • [3] Phase 3, randomized trial (CheckMate 057) of nivolumab (NIVO) vs docetaxel (DOC) in advanced non-squamous (non-SQ) non-small cell lung cancer (NSCLC): Subgroup analyses and patient reported outcomes (PROs)
    Horn, L.
    Brahmer, J.
    Reck, M.
    Borghaei, H.
    Spigel, D. R.
    Steins, M.
    Ready, N. E.
    Chow, L. Q.
    Vokes, E. E.
    Felip, E.
    Holgado, E.
    Barlesi, F.
    Kohlhaeufl, M. J.
    Burgio, M. A.
    Fayette, J.
    Gettinger, S. N.
    Harbison, C. T.
    Li, A.
    Finckenstein, F. G.
    Paz-Ares, L.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S599 - S599
  • [4] Patient-Reported Outcomes (PROs) in OAK: A Phase III Study of Atezolizumab vs Docetaxel in Non-Small-Cell Lung Cancer (NSCLC)
    Bordoni, R.
    Ciardiello, F.
    Von Pawel, J.
    Cortinovis, D.
    He, P.
    Karagiannis, T.
    Ballinger, M.
    Sandler, A.
    Yu, W.
    Felizzi, F.
    Rittmeyer, A.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1913 - S1914
  • [5] Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer (NSCLC): results of the phase 3 CheckMate 078 study
    Wu, Yi-Long
    Lu, Shun
    Cheng, Ying
    Zhou, Caicun
    Wang, Jie
    Mok, Tony
    Zhang, Li
    Tu, Haiyan
    Wu, Lin
    Feng, Jifeng
    Zhang, Yiping
    Luft, Alexander Valeriercich
    Zhou, Jianying
    Ma, Zhiyong
    Lu, You
    Hu, Chengping
    Shi, Yuankai
    Baudelet, Christine
    Li, Zoe
    Chang, Jianhua
    CANCER RESEARCH, 2018, 78 (13)
  • [6] Phase 3, randomized trial (CheckMate 057) of nivolumab (NIVO) vs. docetaxel (DOC) in advanced non-squamous (non-SQ) non-small cell lung cancer (NSCLC) - subgroup analyses and patient reported outcomes (PROs)
    Horn, L.
    Brahmer, J.
    Reck, M.
    Borghaei, H.
    Spigel, D.
    Steins, M.
    Ready, N.
    Chow, L.
    Vokes, E.
    Felip, E.
    Holgado, E.
    Barlesi, F.
    Kohlhaeufl, M.
    Burgio, M.
    Fayette, J.
    Gettinger, S.
    Harbison, C.
    Li, A.
    Finckenstein, F.
    Paz-Ares, L.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 27 - 27
  • [7] Phase 3, Randomized Trial (CheckMate 017) of Nivolumab (NIVO) vs Docetaxel in Advanced Squamous (SQ) Cell Non-Small Cell Lung Cancer (NSCLC)
    Reckamp, Karen
    Brahmer, Julie R.
    Spigel, David R.
    Rizvi, Naiyer A.
    Poddubskaya, Elena
    West, Howard
    Eberhardt, Wilfried E. E.
    Baas, Paul
    Antonia, Scott J.
    Pluzanski, Adam
    Vokes, Everett
    Holgado, Esther
    Waterhouse, David
    Ready, Neal
    Gainor, Justin F.
    Aren Frontera, Osvaldo
    Horn, Leora
    Paz-Ares, Luis
    Li, Ang
    Lynch, Mark
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S174 - S175
  • [8] PHASE 3, RANDOMIZED TRIAL (CHECKMATE 017) OF NIVOLUMAB (NIVO) VS DOCETAXEL IN ADVANCED SQUAMOUS (SQ) CELL NON-SMALL CELL LUNG CANCER (NSCLC)
    Rechamp, Karen
    Spigel, David R.
    Rizvi, Naiyer
    Poddubskaya, Elena
    West, Howard
    Eberhardt, Wilfried
    Baas, Paul
    Antonia, Scott J.
    Pluzanski, Adam
    Vokes, Everett E.
    Holgado, Esther
    Waterhouse, David
    Reddy, Neal
    Gainor, Justin
    Frontera, Osvaldo Aren
    Horn, Leora
    Paz-Ares, Luis
    Zhu, Jin
    Lynch, Mark
    Brahmer, Julie
    Asia-Pacific Journal of Clinical Oncology, 2015, 11 : 130 - 130
  • [9] HEALTH CARE RESOURCE UTILIZATION (HCRU) OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) TREATED WITH NIVOLUMAB VERSUS DOCETAXEL: RESULTS FROM THE CHECKMATE 078 (CM078) TRIAL
    Lawrance, R.
    DeRosa, M.
    Taylor, F.
    Penrod, J. R.
    Shaw, J. W.
    Wang, P. F.
    VALUE IN HEALTH, 2019, 22 : S79 - S79
  • [10] Patient-reported outcomes (PROs) of cemiplimab vs chemotherapy in advanced non-small cell lung cancer (aNSCLC): EMPOWER-Lung 1 histology subgroups
    Sezer, A.
    Kilickap, S.
    Gumus, M.
    Bondarenko, I.
    Ozguroglu, M.
    Gogishvili, M.
    He, X.
    Gullo, G.
    Rietschel, P.
    Quek, R.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1089 - S1089
12345